Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Creo Medical ( (GB:CREO) ) has issued an announcement.
Creo Medical Group has received U.S. FDA clearance for its SpydrBlade™ Flex, a versatile endoscopic device designed for precision in therapeutic endoscopy procedures. This clearance allows Creo to launch the device in the U.S. market, supported by its existing sales network and recent reimbursement code decisions by the American Medical Association. The SpydrBlade™ Flex, part of Creo’s advanced energy GI product range, is expected to enhance the company’s market position by offering a unique solution for complex surgical procedures, potentially benefiting patients, clinicians, and healthcare providers.
More about Creo Medical
Creo Medical is a medical device company specializing in the development and commercialization of minimally invasive electrosurgical devices. The company focuses on bringing advanced energy solutions to endoscopy, aiming to improve patient outcomes through its suite of electrosurgical medical devices powered by its proprietary CROMA technology. This technology integrates multi-modal energy sources to optimize surgical capability, offering safer, less-invasive, and cost-efficient options for medical procedures.
Average Trading Volume: 1,799,390
Technical Sentiment Signal: Sell
Current Market Cap: £61.36M
See more data about CREO stock on TipRanks’ Stock Analysis page.